Functional Outcomes in Older Adults With Fragility Fractures of the Pelvis: The FFP-France Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Observational Assessment of Fragility Fractures of the Pelvis: No study-specific intervention is performed. Diagnostic and therapeutic management is determined by routine clinical practice at each participating center. Clinical, radiological, treatment, and outcome data are collected for observational purposes.
Study summary
Fragility fractures of the pelvis (FFP) are an increasingly common complication of osteoporosis in older adults and are associated with substantial morbidity, loss of independence, and mortality. Despite their clinical impact, FFP remain underdiagnosed, particularly sacral fractures, and their management varies considerably across centers.FFP-France is a French multicenter ambispective observational study designed to describe functional outcomes in adults aged 60 years and older with FFP. The primary objective is to assess functional outcome at 6 months using the Parker Mobility Score. Secondary objectives include describing clinical and radiological characteristics, diagnostic and therapeutic management, pain, autonomy, mortality, osteoporosis management, and factors associated with unfavorable functional recovery.
Eligibility
Primary outcome measure(s)
- Functional Mobility at 6 Months Assessed by the Parker Mobility Score (PMS) — 6 months after the fragility fracture of the pelvis
Functional mobility will be assessed using the Parker Mobility Score (PMS), which evaluates the participant's ability to walk indoors, walk outdoors, and go shopping. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 9, with higher scores indicating greater mobility.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU de Nice | Nice | Alpes Maritimes |
More Centre Hospitalier Universitaire de Nice trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07871084 on ClinicalTrials.gov ↗ ← All trials in France